HCV Archives – Page 3 of 29 – Treatment Action Group

Community Call to Action on Equitable Access to Long-Acting Therapies

February 1, 2023
Dorrit Walsh

The growing pipeline for long-acting therapies and their potential to accelerate various national and global disease elimination goals warrants global community mobilization to ensure equitable access to these therapies.

Advocating for the Integration of Viral Hepatitis Prevention and Treatment for People Who Use Drugs in PEPFAR COPs

January 20, 2023
Dorrit Walsh

On January 24, 2022, Treatment Action Group (TAG), World Hepatitis Alliance (WHA), Harm Reduction International (HRI), the International Network of People Who Use Drugs (INPUD), and the International Drug Policy Consortium (IDPC) will host a webinar, “Advocating for the Integration of Viral Hepatitis Prevention and Treatment for People Who Use Drugs in PEFPFAR COPs."

2022 TAG Update

December 8, 2022
Dorrit Walsh

As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.

Cover of November 2022 TAGline: Reads "TAG at 30" and is an illustration of various protest signs. "Free the Vaccine," "Silence = Death," "Cough Up the TB Money," "Stigma Spreads Disease," etc.

TAGline November 2022

November 3, 2022
Dorrit Walsh

This year’s edition of TAGline commemorates TAG’s 30th anniversary, and these articles explore TAG’s work over the years: what we've accomplished, what we've learned, the continuing obstacles to progress, and what comes next.

Community Mobilization to Ensure Health Systems’ Readiness for Long-Acting Therapies

October 27, 2022
Dorrit Walsh

On November 16, 2022, please join TAG, INPUD and AfroCAB for our webinar “Community Mobilization to Ensure Health Systems’ Readiness for Long-Acting Therapies” at 8:00 a.m. EST / 02:00 p.m. CET / 05:30 IST.

Towards Pandemic Equity: Lessons from 30 Years of Syndemic Activism

October 19, 2022
Dorrit Walsh

By Mike Frick and Mark Harrington The articles in this 30th anniversary issue of TAGline grapple with “pandemic equity,” an increasingly common catchphrase in global health. COVID-19 has shown that “equity,” like its cousins “justice,” “fairness,” and “equality,” is one…

The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation

September 21, 2022
Dorrit Walsh

As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing vast civil society networks, and people living with and affected by malaria, HIV, tuberculosis, and the hepatitis C virus (HCV) across the world, we welcome the efforts leading to the development of an investigational long-acting injectable (LAI) formulation of ivermectin to fight malaria transmission, mdc-STM currently in preclinical stage, and developed by MedinCell.

Treatment Action Group Statement on Retirement of Dr. Anthony S. Fauci

August 23, 2022
Dorrit Walsh

Treatment Action Group (TAG) meets with sadness the announcement by Dr. Anthony S. Fauci of his retirement as Director of the National Institute of Allergy and Infectious Diseases (NIAID), Chief of the NIAID Laboratory of Immunoregulation, and Chief Medical Advisor to President Biden, effective in December 2022.

Treatment Action Group Adds Three New Board Members

August 23, 2022
Dorrit Walsh

As it celebrates its 30th Anniversary year, Treatment Action Group (TAG) announced the election of David Puente, Michael Montero and Ivy Kwan Arce to its Board of Directors.

LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available

August 1, 2022
Dorrit Walsh

Four years after the Medicines Patent Pool (MPP) and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers to ensure commercialization in low- and middle-income countries, generic G/P is not available anywhere.